Stryker Corp
NYSE:SYK

Watchlist Manager
Stryker Corp Logo
Stryker Corp
NYSE:SYK
Watchlist
Price: 353.67 USD -0.3% Market Closed
Market Cap: 135.3B USD

Intrinsic Value

The intrinsic value of one SYK stock under the Base Case scenario is 327.48 USD. Compared to the current market price of 353.67 USD, Stryker Corp is Overvalued by 7%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SYK Intrinsic Value
327.48 USD
Overvaluation 7%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Stryker Corp

What is Valuation History?
Ask AI Assistant
What other research platforms think about SYK?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is SYK valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Stryker Corp.

Explain Valuation
Compare SYK to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Stryker faces intensifying competition in orthopedic implants, particularly as rivals like Zimmer Biomet and Johnson & Johnson expand their robotic-assisted surgery capabilities. Losing pricing power and market share in this key revenue driver could pressure margins.

Acquisitions, such as the purchase of Wright Medical, bring integration challenges and heighten the risk of execution missteps. If Stryker fails to realize anticipated cost synergies or manage operational complexities, its earnings and growth could be adversely affected.

A slowdown in elective procedures or more restrictive hospital budgets could undermine demand for Stryker’s surgical equipment and implants, disproportionately impacting the company’s high-margin businesses in orthopedic reconstruction and medical instruments.

Bull Theses

Stryker’s significant investments in surgical robotics, exemplified by its Mako robotic-arm system, position the company for sustained leadership in the fast-growing orthopedic surgical space, supporting premium pricing and high customer switching costs.

Consistent capital deployment toward strategic acquisitions has enabled Stryker to broaden its product portfolio across neurotechnology, spine, and medical surgical equipment. This strategy adds incremental revenue streams and allows cross-selling opportunities in a range of clinical settings.

Strong relationships with hospitals and surgeons, coupled with Stryker’s robust R&D engine, bolster the company’s ability to innovate. This competitive moat should help Stryker defend and expand its share in high-demand fields like joint replacement and endoscopy.

Show More Less
How do you feel about SYK?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Stryker Corp

Current Assets 13.7B
Cash & Short-Term Investments 3.3B
Receivables 3.6B
Other Current Assets 6.7B
Non-Current Assets 33.3B
PP&E 3.7B
Intangibles 25.1B
Other Non-Current Assets 4.5B
Current Liabilities 7.4B
Other Current Liabilities 7.4B
Non-Current Liabilities 17.9B
Long-Term Debt 14.8B
Other Non-Current Liabilities 3B
Efficiency

Free Cash Flow Analysis
Stryker Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Stryker Corp

Revenue
24.4B USD
Cost of Revenue
-8.6B USD
Gross Profit
15.7B USD
Operating Expenses
-10.3B USD
Operating Income
5.4B USD
Other Expenses
-2.5B USD
Net Income
2.9B USD
Fundamental Scores

SYK Profitability Score
Profitability Due Diligence

Stryker Corp's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
Healthy Operating Margin
Positive 3Y Average ROE
55/100
Profitability
Score

Stryker Corp's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

SYK Solvency Score
Solvency Due Diligence

Stryker Corp's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
High Interest Coverage
Low D/E
Long-Term Solvency
62/100
Solvency
Score

Stryker Corp's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SYK Price Targets Summary
Stryker Corp

Wall Street analysts forecast SYK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SYK is 437.04 USD with a low forecast of 320.88 USD and a high forecast of 488.25 USD.

Lowest
Price Target
320.88 USD
9% Downside
Average
Price Target
437.04 USD
24% Upside
Highest
Price Target
488.25 USD
38% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Previous Payment
-
Today
Next Payment
-
Today
Dec 26, 2025
Previous Payment
-
Next Payment
-
Ex-Dividend Date
-
Shareholder Yield

Current shareholder yield for SYK is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

SYK Insider Trading
Buy and sell transactions by insiders

SYK News

Other Videos
What is the Intrinsic Value of one SYK stock?

The intrinsic value of one SYK stock under the Base Case scenario is 327.48 USD.

Is SYK stock undervalued or overvalued?

Compared to the current market price of 353.67 USD, Stryker Corp is Overvalued by 7%.

Back to Top